Results 71 to 80 of about 19,354 (307)

Rezafungin Utilisation in Real Life—FungiScope Results From Europe and the United States

Mycoses, Volume 68, Issue 9, September 2025.
ABSTRACT Background Rezafungin, a novel echinocandin with once‐weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While clinical trial data support its efficacy and safety, real‐world experience remains limited.
Ilana Reinhold, Giovanni Mori, Massimiliano Lanzafame, Alessandro Limongelli, Antonio Vena, Julia Götz, Stilla Bauernfeind, Frank Hanses, Lukas Tometten, Michael Mayer, Ansgar Rieke, Ana Soriano‐Martin, Maricela Valerio, Jose A. Vazquez, Patrick Yue, Laman Rahimli, Nijat Azimli, Ertan Sal, Jon Salmanton‐García, Natalia Vasenda, Rosanne Sprute, Jannik Stemler, Sebastian Wingen‐Heimann, Oliver A. Cornely, Danila Seidel   +24 more
wiley   +1 more source

Chronic kidney disease and valvular heart disease: State of the art

Physiological Reports, Volume 13, Issue 18, September 2025.
Abstract Chronic kidney disease (CKD) and valvular heart disease (VHD) frequently coexist and are associated with a significant increase in morbidity and mortality. Their interplay is complex and multifactorial, involving shared pathophysiological mechanisms such as chronic inflammation, mineral and bone disorder, vascular and valvular calcification ...
S. Saltarocchi, M. D'Abramo, P. De Orchi, F. Spunticchia, M. Totaro, E. M. Cirio, F. Miraldi   +6 more
wiley   +1 more source

Tricuspid valve dysplasia in dogs [PDF]

, 2018
A general overview of tricuspid valve dysplasia in dogs is presented in this review. This congenital disease has been described in numerous large dog breeds but especially the Labrador retriever is predisposed.
Bavegems, Valérie, Broeckx, Bart, De Rooster, Hilde, Favril, Sophie, Peelman, Luc, Smets, Pascale   +5 more
core   +1 more source

Long-term follow-up of elderly patients subjected to aortic valve replacement with mechanical prostheses [PDF]

, 2009
We propose to analyse the long-term follow-up in patients older than 65 years of age who received a mechanical valve in the aortic position, using death and prosthetic-related complications as endpoints.
Antunes, MJ, Antunes, PE, Coutinho, GF, Pancas, R   +3 more
core   +1 more source

A Case Series of Valve‐in‐Valve Transcatheter Aortic Valve Replacement in Stentless Bioprosthetic Valves Using Self‐Expanding Platform With Minimalist Approach

Catheterization and Cardiovascular Interventions, Volume 106, Issue 2, Page 992-1001, August 1, 2025.
ABSTRACT Valve‐in‐valve (ViV) Transcatheter aortic valve replacement (TAVR) has emerged as a valid treatment option in symptomatic patients with failed aortic bioprosthetic valves, most especially in those with intermediate, high or prohibitive risk of surgery. Due to the unique design of stentless bioprosthetic valves with absence of visible posts and
Adeogo Akinwale Olusan, Raj Rajendra, Elved Roberts, Jan Kovac   +3 more
wiley   +1 more source

Pregnancy outcomes in women with a mitral valve prosthesis: A systematic review and meta-analysisCentral MessagePerspective

JTCVS Open, 2023
Objectives: To evaluate the ongoing debate concerning the choice of valve prosthesis for women requiring mitral valve replacement (MVR) and who wish to conceive. Bioprostheses are associated with risk of early structural valve deterioration.
Pepijn Grashuis, BSc, Shanti D.M. Khargi, BSc, Kevin Veen, BSc, PhD, Azzeddine el Osrouti, BSc, Shirin Bemelmans-Lalezari, MD, PhD, Jérôme M.J. Cornette, MD, PhD, Jolien W. Roos-Hesselink, MD, PhD, Johanna J.M. Takkenberg, MD, PhD, Mostafa M. Mokhles, MD, PhD   +8 more
doaj   +1 more source

Mitroflow aortic pericardial bioprosthesis — clinical performance☆☆☆ [PDF]

European Journal of Cardio-Thoracic Surgery, 2009
Advancing life expectancy with the increased prevalence of aortic valve degenerative disease brings the need for an aortic bioprosthesis with excellent haemodynamic performance and comparable durability. The Mitroflow bioprosthesis has been on the worldwide market, except in the United States, since 1982, while the current model (1991) has only ...
William Robert Eric, Jamieson, Reiner, Koerfer, Charles A, Yankah, Armin, Zittermann, Robert I, Hayden, Hilton, Ling, Roland, Hetzer, William B, Dolman   +7 more
openaire   +2 more sources

Bioprosthetic Valve Fracturing in Valve‐in‐Valve TAVI: Clinical and Echocardiographic Outcomes in Failing Perimount Aortic Bioprostheses—A Multicenter Registry

Catheterization and Cardiovascular Interventions, Volume 106, Issue 2, Page 1409-1420, August 1, 2025.
ABSTRACT Background Data comparing clinical and hemodynamic outcomes of bioprosthetic valve fracturing (BVF) and “standard”‐postdilatation during valve‐in‐valve transcatheter heart valve implantation (ViV‐TAVI) are lacking. The authors aimed to analyze hemodynamic and clinical outcomes of BVF compared to “standard”‐postdilatation during ViV‐TAVI ...
Hendrik Ruge, Melchior Burri, Julia Schreyer, Teodora‐Cristiana Georgescu, Derk Frank, Won‐Keun Kim, Ole de Backer, Martin Beyer, Andreas Schäfer, Chiara Fraccaro, Giuseppe Tarantini, Erion Xhepa, Michael Joner, Markus Krane, Héctor Alfonso Alvarez Covarrubias   +14 more
wiley   +1 more source

Restoration of a Stuck Leaflet

Catheterization and Cardiovascular Interventions, Volume 106, Issue 1, Page 527-529, July 1, 2025.
ABSTRACT Severe aortic regurgitation (AR) for a leaflet malfunction after transcatheter aortic valve implantation (TAVI) is a dreadful complication that can lead even to cardiogenic shock. New valve's design has reduced the rate of paravalvular regurgitation, however central regurgitation is still a challenging complication.
Elisa Tomarelli, Gianluca Di Pietro, Gennaro Sardella, Massimo Mancone   +3 more
wiley   +1 more source

Results of matching valve and root repair to aortic valve and root pathology [PDF]

, 2011
ObjectiveFor patients with aortic root pathology and aortic valve regurgitation, aortic valve replacement is problematic because no durable bioprosthesis exists, and mechanical valves require lifetime anticoagulation. This study sought to assess outcomes
Lars G. Svensson, Lillian H. Batizy, Eugene H. Blackstone, A. Marc Gillinov, Michael C. Moon, Richard S. D’Agostino, Edward M. Nadolny, William J. Stewart, Brian P. Griffin, Donald F. Hammer, Richard Grimm, Bruce W. Lytle, Svensson, Svensson, Miller, Karck, Kallenbach, Akins, Zellner, David, Sarsam, David, Svensson, Schafers, Leyh, van Son, Burkhart, Svensson, David, De Paulis, Pethig, Harringer, Frater, Casselman, El Khoury, Hopkins, Wolfe, Banbury, Rubin, Rosenbaum, Blackstone, Drake, Blackstone, Breiman, Silverman, Svensson, Svensson, Pettersson, Svensson, Svensson, Svensson, Miller   +51 more
core   +2 more sources